Literature DB >> 25949893

Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent.

Christopher G Kanakry1, Sudipto Ganguly1, Leo Luznik1.   

Abstract

In two recent publications, we demonstrated that after allogeneic stimulation, regulatory T cells (Tregs) increase expression of aldehyde dehydrogenase (ALDH), the major in vivo mechanism of cyclophosphamide detoxification, thereby becoming cyclophosphamide resistant. Differential ALDH expression may explain why cyclophosphamide has pro- and anti-inflammatory effects that are temporally and contextually dependent.

Entities:  

Keywords:  aldehyde dehydrogenase, ALDH, allogeneic, BMT, cyclophosphamide, post-transplantation cyclophosphamide, regulatory T cell, tolerance, Treg

Year:  2015        PMID： 25949893      PMCID： PMC4404790          DOI： 10.4161/2162402X.2014.974393

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  PROLONGATION OF HOMOGRAFT SURVIVAL IN MICE WITH SINGLE DOSES OF CYCLOPHOSPHAMIDE.

Authors:  M C BERENBAUM; I N BROWN
Journal:  Nature       Date:  1963-10-05       Impact factor: 49.962

2.  Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?

Authors:  Y Tomita; H Mayumi; M Eto; K Nomoto
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

3.  Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity.

Authors:  L Polak; J L Turk
Journal:  Nature       Date:  1974-06-14       Impact factor: 49.962

4.  Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.

Authors:  D Busse; F W Busch; F Bohnenstengel; M Eichelbaum; P Fischer; J Opalinska; K Schumacher; E Schweizer; H K Kroemer
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

6.  Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Sven Brode; Tim Raine; Paola Zaccone; Anne Cooke
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

Review 7.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

8.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

9.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307
  10 in total
  9 in total

1.  Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Authors:  Aurélie Hanoteau; Coralie Henin; David Svec; Charlotte Bisilliat Donnet; Sébastien Denanglaire; Didier Colau; Pedro Romero; Oberdan Leo; Benoit Van den Eynde; Muriel Moser
Journal:  Oncoimmunology       Date:  2017-05-11       Impact factor: 8.110

2.  Functional role of regulatory T cells in B cell lymphoma and related mechanisms.

Authors:  Wei Wu; Jun Wan; Ruixiang Xia; Zhenqi Huang; Jing Ni; Mingzhen Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Authors:  Orly R Klein; Jessica Buddenbaum; Noah Tucker; Allen R Chen; Christopher J Gamper; David Loeb; Elias Zambidis; Nicolas J Llosa; Jeffrey S Huo; Nancy Robey; Mary Jo Holuba; Yvette L Kasamon; Shannon R McCurdy; Richard Ambinder; Javier Bolaños-Meade; Leo Luznik; Ephraim J Fuchs; Richard J Jones; Kenneth R Cooke; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-22       Impact factor: 5.742

4.  Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.

Authors:  Koen van Besien; Andrew Artz; Richard E Champlin; Danielle Guarneri; Michael R Bishop; Julianne Chen; Usama Gergis; Tsiporah Shore; Hongtao Liu; Gabriela Rondon; Sebastian A Mayer; Samer A Srour; Wendy Stock; Stefan O Ciurea
Journal:  Blood Adv       Date:  2019-06-25

5.  Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Authors:  Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-13       Impact factor: 5.742

6.  Characterization of the T-cell Repertoire after Autologous HSCT in Patients with Ankylosing Spondylitis.

Authors:  E A Komech; I V Zvyagin; M V Pogorelyy; I Z Mamedov; D A Fedorenko; Y B Lebedev
Journal:  Acta Naturae       Date:  2018 Apr-Jun       Impact factor: 1.845

Review 7.  Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.

Authors:  Natalia S Nunes; Christopher G Kanakry
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

8.  Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.

Authors:  Ashley D Hadjis; Natalia S Nunes; Shanzay M Khan; Rochelle E Fletcher; Alessandra de Paula Pohl; David J Venzon; Michael A Eckhaus; Christopher G Kanakry
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

9.  Ovalbumin-Derived Peptides Activate Retinoic Acid Signalling Pathways and Induce Regulatory Responses Through Toll-Like Receptor Interactions.

Authors:  Mónica Martínez-Blanco; Leticia Pérez-Rodríguez; Daniel Lozano-Ojalvo; Elena Molina; Rosina López-Fandiño
Journal:  Nutrients       Date:  2020-03-20       Impact factor: 5.717
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.